This study is currently recruiting participants.
Number
001621-H
Sponsoring Institute
National Heart, Lung and Blood Institute (NHLBI)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Female Min Age: 18 Years Max Age: 120 Years
Referral Letter Required
No
Population Exclusion(s)
Pregnant Women;Children;Male
Keywords
Lupus; Chronic Inflammation
Recruitment Keyword(s)
None
Condition(s)
Systemic Lupus Erythematosus (Sle)
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Dietary Supplement: Nicotinamide Riboside
Supporting Site
National Heart, Lung, and Blood Institute
Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism. Nicotinamide adenine dinucleotide (NAD)+ boosting with nicotinamide riboside blunts type 1 IFN activation in-vivo in monocytes of healthy subjects and ex-vivo in SLE subjects. These findings support the proposal of the hypothesis that NAD+ boosting by NR supplementation will modulate metabolic pathways in lupus and blunt type 1 interferon signaling. Moreover, as type 1 interferon drives endothelial dysfunction, linked to increased cardiovascular risk, the effect of NR on endothelial function will be examined.
Objectives:
Primary Objective: Evaluate the effect of NR vs. placebo on immunometabolic and inflammatory remodeling in female SLE subjects:
Exploratory Objective: Compare and characterize myeloid cell bioenergetic and immunometabolic profiles in healthy control and SLE female subjects
Endpoints:
Primary Endpoint:
The primary end point will be to assess the effect of NR on blunting type I IFN signaling by measuring monocytic secretion of IFN-beta secretion compared to baseline in response to placebo vs. NR supplemented in SLE study subjects.
Exploratory Endpoints:
Healthy control vs. SLE subjects:
-Compare type I IFN transcript profiles in monocytes and neutrophils at baseline and in response to activation.
-Assess cell bioenergetics including: 1) monocyte and neutrophil metabolic flux mass spectroscopy of 13C-glucose and 13Cglutamine analysis to investigate their metabolic fates; (iii) Mitochondrial oxygen consumption (using glucose, amino acid, and fatty acid substrates) and glycolysis rates.
SLE baseline vs. NR/placebo supplementation:
Baseline vs. 6 weeks of NR/placebo:
-Assess effect of NR on bioenergetics by measuring steady-state metabolite levels comparing changes in placebo vs. NR groups in monocytes and neutrophils.
Baseline vs. 12 weeks of NR/placebo:
-Whole blood NAD+ levels (batched and measured at the end of study enrollment period)
-Explore effects of NR on gene regulation using monocyte and neutrophils by RNA-seq and chromatin remodeling analysis.
-Determine the effect of NR vs placebo on endothelial dysfunction in SLE subjects
--Back to Top--
INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: SLE subjects: -Female subjects 18 years or older who meets > 3 of 11 modified Am. Coll. of Rheumatology (ACR) (1997) Revised Criteria for SLE and mild/moderate disease activity defined as an SLE Disease Activity Index 2000(SLEDAI 2K) between zero and less than or equal to 14 at screening; -If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for at least 4 weeks prior to screening; -If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine, dose must have been stable for the 12 weeks prior to screening. The max. allowed doses - hydroxychloroquine 400 mg/day, chloroquine phosphate 500 mg/day and quinacrine 100 mg/day; -If on immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus); dose must have been stable for the 12 weeks prior to screening -Subjects of childbearing potential must agree to practice effective birth control for the duration of the study; -Stated willingness to comply with all study procedures and availability for the duration of the study; -Agreement to adhere to Lifestyle Considerations throughout study duration; -Ability of subject to understand and the willingness to sign a written informed consent document. Control subjects: -Female subjects 18 years or older -No history of autoimmune or inflammatory disease; EXCLUSION CRITERIA: SLE Subjects: -Active renal or central nervous system disease or major renal or hepatic dysfunction; -Treatment with rituximab, belimumab or any other biologic agent within the 6 months prior to screening -Treatment with cyclophosphamide or IVIG within the 6 months prior to screening and or increase in glucocorticoid dose within 4 weeks of screening; -Dietary vitamin B3 or tryptophan supplementation within 6 weeks of screening. -Pregnancy or lactation (nursing) -Treatment with another investigational drug or other intervention within 6 months of screening Control Subjects: -Inability to sign consent -Dietary vitamin B3 or tryptophan supplementation within 6 weeks -Pregnancy or nursing Pregnant women are excluded from participation on this study. Self-reported pregnancy status may be accepted from female control participants of child-bearing potential for a blood draw which is considered a minimal risk procedure.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
SLE subjects:
-Female subjects 18 years or older who meets > 3 of 11 modified Am. Coll. of Rheumatology (ACR) (1997) Revised Criteria for SLE and mild/moderate disease activity defined as an SLE Disease Activity Index 2000(SLEDAI 2K) between zero and less than or equal to 14 at screening;
-If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for at least 4 weeks prior to screening;
-If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine, dose must have been stable for the 12 weeks prior to screening. The max. allowed doses - hydroxychloroquine 400 mg/day, chloroquine phosphate 500 mg/day and quinacrine 100 mg/day;
-If on immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus); dose must have been stable for the 12 weeks prior to screening
-Subjects of childbearing potential must agree to practice effective birth control for the duration of the study;
-Stated willingness to comply with all study procedures and availability for the duration of the study;
-Agreement to adhere to Lifestyle Considerations throughout study duration;
-Ability of subject to understand and the willingness to sign a written informed consent document.
Control subjects:
-Female subjects 18 years or older
-No history of autoimmune or inflammatory disease;
EXCLUSION CRITERIA:
SLE Subjects:
-Active renal or central nervous system disease or major renal or hepatic dysfunction;
-Treatment with rituximab, belimumab or any other biologic agent within the 6 months prior to screening
-Treatment with cyclophosphamide or IVIG within the 6 months prior to screening and or increase in glucocorticoid dose within 4 weeks of screening;
-Dietary vitamin B3 or tryptophan supplementation within 6 weeks of screening.
-Pregnancy or lactation (nursing)
-Treatment with another investigational drug or other intervention within 6 months of screening
Control Subjects:
-Inability to sign consent
-Dietary vitamin B3 or tryptophan supplementation within 6 weeks
-Pregnancy or nursing
Pregnant women are excluded from participation on this study. Self-reported pregnancy status may be accepted from female control participants of child-bearing potential for a blood draw which is considered a minimal risk procedure.
Principal Investigator
Referral Contact
For more information: